Drugs / Blonanserin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT02287584 | Dec 2014 → Dec 2018 | schizophrenia | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01516424 | Feb 2012 → Feb 2013 | schizophrenia | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03784222 | Jan 2019 → Nov 2022 | CGF1, schizophrenia | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Blonanserin | “AIM: To explore the optimal dose of blonanserin transdermal patch (BNS-P) based on baseline psychiatric symptomatic characteristics during acute schizophrenia.” PMID 39428614 ↗ Oct 2024 |
| Known as | AD-5423 | ChEMBL registry synonym — accepted as the source's own label CHEMBL178803 ↗ |
| Known as | Blonanserina | ChEMBL registry synonym — accepted as the source's own label CHEMBL178803 ↗ |
| Known as | Blonanserine | ChEMBL registry synonym — accepted as the source's own label CHEMBL178803 ↗ |
| Known as | BNS-P | “AIM: To explore the optimal dose of blonanserin transdermal patch (BNS-P) based on baseline psychiatric symptomatic characteristics during acute schizophrenia.” PMID 39428614 ↗ Oct 2024 |
| Known as | DSP-5423 | ChEMBL registry synonym — accepted as the source's own label CHEMBL178803 ↗ |
| Action | Inhibit | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL178803 ↗ |
| Modality | Small molecule | — CHEMBL178803 ↗ |
| Route | Oral | “4 mg P.O. twice per day after meals” PMID 35443947 ↗ Apr 2022 |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL178803 ↗ |
| Target | DRD3 | “Dopamine D3 receptor antagonist” CHEMBL178803 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL178803 ↗ |